Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

NCT00699751 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00699751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00699751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
June 12, 2008
Completion date
February 13, 2014
Enrollment
921 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, hormone refractory prostate cancer